Acamprosate in the treatment of alcohol dependence

Bibliography

• GRANT BF, DAWSON DA, STINSON FS, CHOU SP, DUFOUR MC, PICKERING RP: The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991 — 1992 and 2001 —2002. Drug Alcohol Depend. (2004) 74(3):223–234.
   PubMed Web of Science ®Google Scholar
• CAETANO R, TAM TW: Prevalence and correlates of DSM-IV and ICD-10 alcohol dependence: 1990 US National Alcohol Survey. Alcohol Alcohol. (1995) 30(2):177–186.
   PubMed Web of Science ®Google Scholar
• MCGINNIS JM, FOEGE WH: Actual causes of death in the United States. JAMA (1993) 270(18):2207–2212.
   PubMed Web of Science ®Google Scholar
• REGIER DA, FARMER ME, RAE DS et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA (1990) 264(19):2511–2518.
   Google Scholar
• HARWOOD H: Updating estimates of the economic costs of alcohol abuse in the united states: estimates, update methods, and data. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism. US Department of Health and Human Services, Rockville, MD (2000).
   Google Scholar
• GARBUTT JC, WEST SL, CAREY TS, LOHR KN, CREWS FT: Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA (1999) 281(14):1318–1325.
   PubMed Web of Science ®Google Scholar
• •Review of pharmacological treatments for alcohol dependence.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. American Psychiatric Association, Washington, DC, USA (2004).
   Google Scholar
• LITTLETON J: Acamprosate in alcohol dependence: how does it work? Addiction (1995) 90(9):1179–1188.
   PubMed Web of Science ®Google Scholar
• •Overview of the pharmacological mechanism of action of acamprosate.
   Google Scholar
• SWIFT RM: Drug therapy for alcohol dependence. N Engl. J. Med. (1999) 340(19):1482–1490.
   PubMed Web of Science ®Google Scholar
• MIHIC SJ, HARRIS RA: Alcohol actions at the GABA-A receptor/chloride channel complex. In: Pharmacological Effects of Ethanol on the Nervous System. Deitrich RA et al. (Eds) CRC Press, Boca Raton, USA (1996):51–72.
   Google Scholar
• NEVO I, HAMON M: Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem. Int. (1995) 26(4):305–336.
   PubMed Web of Science ®Google Scholar
• FAINGOLD CL, N'GOUEMO P, RIAZ Ethanol and neurotransmitter interactions - from molecular to integrative effects. Prog. Neurobiol (1998) 55(5):509–535.
   PubMed Web of Science ®Google Scholar
• KOOB GF, ROBERTS AJ, SCHULTEIS G et al.: Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin. Exp. Res. (1998) 22(1):3–9.
   PubMed Web of Science ®Google Scholar
• WHITWORTH AB, FISCHER F, LESCH OM et al.: Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet (1996) 347(9013):1438–1442.
   PubMed Web of Science ®Google Scholar
• O'BRIEN CP, MCLELLAN AT: Addiction medicine. JAMA (1997) 277(23):1840–1841.
   PubMed Web of Science ®Google Scholar
• FRIEDMANN PD, SAITZ R, SAMET JH: Management of adults recovering from alcohol or other drug problems: relapse prevention in primary care. JAMA (1998) 279(15):1227–1231.
   PubMed Web of Science ®Google Scholar
• FINNEY JW, HAHN AC, MOOS RH: The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction (1996) 91(12):1773–1796.
   PubMed Web of Science ®Google Scholar
• HUGHES JC, COOK CC: The efficacy of disulfiram: a review of outcome studies. Addiction (1997) 92(4):381–395.
   PubMed Web of Science ®Google Scholar
• CHICK J: Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf (1999) 20(5):427–435.
   PubMed Web of Science ®Google Scholar
• KRANZLER HR: Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol. (2000) 35(6):537–547.
   PubMed Web of Science ®Google Scholar
• VOLPICELLI JR, ALTERMAN Al, HAYASHIDA M, O'BRIEN CP: Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry (1992) 49(10:876–880.
   PubMedGoogle Scholar
• O'MALLEY SS, JAFFE AJ, CHANG G, SCHOTTENFELD RS, MEYER RE, ROUNSAVILLE B: Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry (1992) 49(11):881–887.
   PubMed Web of Science ®Google Scholar
• ROHSENOW DJ: What place does naltrexone have in the treatment of alcoholism? CNS Drugs (2004) 18(9):547–560.
   PubMed Web of Science ®Google Scholar
• ANTON RF, SWIFT RM: Current pharmacotherapies of alcoholism: a US perspective. Am. J. Addict. (2003) 12\(Suppl. 1):553–568.
   Google Scholar
• STREETON C, WHELAN G: Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. (2001) 36(0:544–552.
   PubMedGoogle Scholar
• KRANZLER HR, VAN KIRK J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. (2001) 25(9):1335–1341.
   PubMed Web of Science ®Google Scholar
• KRYSTAL JH, CRAMER JA, KROL WF, KIRK GF, ROSENHECK RA: Naltrexone in the treatment of alcohol dependence. N Engl J. Med. (2001) 345(24):1734–1739.
   PubMed Web of Science ®Google Scholar
• MONTI PM, ROHSENOW DJ, HUTCHISON KE et al.: Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol. Clin. Exp. Res. (1999) 23(8):1386–2394.
   PubMed Web of Science ®Google Scholar
• MASON BJ: Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J. Clin. Psychiatry (2001) 62\(Suppl. 20):42–48.
   Google Scholar
• •Review of the clinical trials reporting the effectiveness of acamprosate for the treatment of alcohol dependence.
   Google Scholar
• CHABENAT C, LADURE P, MOORE N, BOUCLY P, BOISMARE F: Application of an analytical method to calcium acetylhomotaurinate determination in urine. Arzneimittelforschung (1989) 39(11):1413–1414.
   PubMed Web of Science ®Google Scholar
• GIRAULT J, GOBIN P, FOURTILLAN JB: Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. Chromatogr. (1990) 530(2):295–305.
   Google Scholar
• SAIVIN S, HULOT T, CHABAC S, POTGIETER A. DURBIN P, HOUIN G: Clinical pharmacokinetics of acamprosate. Clin. Pharmacokinet. (1998) 35(5):331–345.
   PubMed Web of Science ®Google Scholar
• •Review of the pharmacokinetic properties of acamprosate.
   Google Scholar
• WILDE MI, WAGSTAFF AJ: Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs (1997) 53(0:1038–1053.
   Google Scholar
• NO AUTHORS LISTED]: Acamprosate. Drugs R • D (2002) 3(1):13–18.
   PubMedGoogle Scholar
• DURBIN P, HULOT T, CHABAC S: Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral Symposium. Soyka M (Ed.), Springer, Stuttgart, Germany (1995):47–64.
   Google Scholar
• JOHNSON BA, O'MALLEY SS, CIRAULO DA et al.: Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J. Clin. Psychopharmacol (2003) 23(3):281–293.
   Google Scholar
• MASON BJ, GOODMAN AM, DIXON RM et al.: A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmaco/ogy (2002) 27(4):596–606.
   PubMed Web of Science ®Google Scholar
• DE WITTE P, LITTLETON J, PAROT P, KOOB G: Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs (2005) 19(6):517–537.
   PubMed Web of Science ®Google Scholar
• DE WITTE P, BACHTELER D, SPANAGEL R: Acamprosate: preclinical data. In: Drugs for Relapse Prevention of Alcoholism. Spanagel R, Mann KF (Eds), Birkhäuser Verlag, Switzerland (2005):73–83.
   Google Scholar
• HOFFMAN PL: NMDA receptors in alcoholism. Int. Rev. NeurobioL (2003) 56:35–82.
   PubMed Web of Science ®Google Scholar
• KUMARI M, TICKU MK: Regulation of NMDA receptors by ethanol. Frog. Drug Res. (2000) 54:152–189.
   PubMedGoogle Scholar
• RAMMES G, MAHAL B, PUTZKE J et al.: The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmaco/ogy (2001) 40(6):749–760.
   PubMed Web of Science ®Google Scholar
• SPANAGEL R, HOLTER SM, ALLINGHAM K, LANDGRAF R, ZIEGLGANSBERGER W: Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur. J. Pharmacol (1996) 305(1-3):39–44.
   Google Scholar
• BOISMARE F, DAOUST M, MOORE N et al.: A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? PharmacoL Biochem. Behav. (1984) 21(5):787–789.
   Google Scholar
• GEWISS M, HEIDBREDER C, OPSOMER L, DURBIN P, DE WITTE P: Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol. (1991) 26(2):129–137.
   PubMed Web of Science ®Google Scholar
• HEYSER CJ, SCHULTEIS G, DURBIN P, KOOB GF: Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology (1998) 18(2):125–133.
   PubMed Web of Science ®Google Scholar
• LE MAGNEN J, TRAN G, DURLACH J, MARTIN C: Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol (1987) 4(2):97–102.
   PubMed Web of Science ®Google Scholar
• NAASSILA M, HAMMOUMI S, LEGRAND E, DURBIN P, DAOUST M: Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol. Clin. Exp. Res. (1998) 22(4):802–809.
   Google Scholar
• ZEISE ML, KASPAROV S, CAPOGNA M, ZIEGLGANSBERGERW: Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. (1993) 231(1):47–52.
   PubMed Web of Science ®Google Scholar
• ROSSETTI ZL, CARBONI S: Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur. j Pharmacol. (1995) 283(1-3):177–183.
   PubMed Web of Science ®Google Scholar
• DAHCHOUR A, DE WITTE P, BOLO N et al.: Central effects of acamprosate: part I. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. (1998) 82(2):107–114.
   Google Scholar
• AL QATARI M, BOUCHENAFA 0, LITTLETON J: Mechanism of action of acamprosate: part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol. Clin. Exp. Res. (1998) 22(4):810–814.
   Google Scholar
• MAYER S, HARRIS B, GIBSON DA et al.: Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol. Clin. Exp. Res. (2002) 26(5):655–662.
   PubMed Web of Science ®Google Scholar
• POPP RL, LOVINGER DM: Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur. j Pharmacol. (2000) 394(2-3):221–231.
   PubMed Web of Science ®Google Scholar
• HARRIS BR, GIBSON DA, PRENDERGAST MA et aL: The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate Type 5 receptors and N-methyl-D-aspartate receptors. Alcohol. Clin. Exp. Res. (2003) 27(11):1724–1735.
   PubMed Web of Science ®Google Scholar
• HARRIS BR, PRENDERGAST Mk GIBSON DA et al.: Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res. (2002) 26(12):1779–1793.
   Google Scholar
• HARRIS BR, FERCHMIN PA, BLANCHARD JA et al.: The sodium salt of acamprosate inhibits the potentiation of NMDA responses by a selective mGluR5 agonist (Abstr.). Proceedings of the 27th Annual Research Society on Alcoholism Scientific Meeting, Vancouver, Canada (2004).
   Google Scholar
• PELC I, VERBANCK P, LE BON 0, GAVRILOVIC M, LION K, LEHERT P: Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br. J. Psychiatry (1997) 171:73–77.
   Google Scholar
• •One of three clinical trials demonstrating the efficacy and safety of acamprosate submitted for FDA approval.
   Google Scholar
• SASS H, SOYKA M, MANN K, ZIEGLGANSBERGER W: Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry (1996) 53(8):673–680.
   PubMed Web of Science ®Google Scholar
• •One of three clinical trials demonstrating the efficacy and safety of acamprosate submitted for FDA approval.
   Google Scholar
• PAILLE FM, GUELFI JD, PERKINS AC, ROYER RJ, STERU L, PAROT P: Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. (1995) 30(2):239–247.
   PubMed Web of Science ®Google Scholar
• •One of three clinical trials demonstrating the efficacy and safety of acamprosate submitted for FDA approval.
   Google Scholar
• LHUINTRE JP, DAOUST M, MOORE ND et al.: Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet (1985) 1(8436):1014–1016.
   PubMed Web of Science ®Google Scholar
• LHUINTRE JP, MOORE N, TRAN G et al.: Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. (1990) 25(6):613–622.
   PubMed Web of Science ®Google Scholar
• ROUSSAUX JP, HERS D, FERAUGE M: Does Acamprosate diminish the appetite for alcohol in weaned alcoholics? Pharm. Belg. (1996) 51:65–68.
   PubMedGoogle Scholar
• NAMKOONG K, LEE B-0, LEE P-G et al.: Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. (2003) 38(2):135–141.
   Google Scholar
• BALTIERI DA, DE ANDRADE AG: Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Rev. Bras. Psiquiatr. (2003) 25(3):156–159.
   PubMedGoogle Scholar
• BARRIAS JA, CHABAC S, FERREIRA L: Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiqiatria Clinica (1997) 18:149–160.
   Google Scholar
• BESSON J, AEBY F, KASAS A. LEHERT P, POTGIETER A: Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol. Clin. Exp. Res. (1998) 22(3):573–579.
   Google Scholar
• POLDRUGO F: Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction (1997) 92(11):1537–1546.
   PubMed Web of Science ®Google Scholar
• TEMPESTA E, JANIRI L, BIGNAMINI A, CHABAC S, POTGIETER A: Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. (2000) 35(2):202–209.
   PubMed Web of Science ®Google Scholar
• CHICK J, HOWLETT H, MORGAN MY, RITSON B: United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. (2000) 35(2):176–187.
   PubMed Web of Science ®Google Scholar
• GEERLINGS PJ, ANSOMS C, VAN DEN BRINK W: Acamprosate and prevention of relapse alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patients in the Netherlands, Belgium and Luxembourg. Eur. Addict. Res. (1997) 3(3):129–137.
   Google Scholar
• GUAL A, LEHERT P: Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. (2001) 36(5):413–418.
   PubMed Web of Science ®Google Scholar
• LADEWIG D, KNECHT T, LEHER P, FENDL A: [Acamprosate - a stabilizing factor in long-term withdrawal of alcoholic patients]. Ther. Umsch. (1993) 50(3):182–188.
   PubMedGoogle Scholar
• PELC I, LE BON 0, VERBANCK P, LEHERT P, OPSOMER L: Calcium acetyl homotaurinate for maintaing abstinence in weaned alcoholic patients: a placebo controlled double-blind multi-centre study. In: Novel Pharmacological Interventions for Alcoholism. Naranjo CA et al. (Eds), Springer-Verlag, New York, USA (1992):348–352.
   Google Scholar
• KIEFER F, JAHN H, TARNASKE T et al.: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2003) 60(1):92–99.
   PubMed Web of Science ®Google Scholar
• MASON BJ, GOODMAN AM, CHABAC S, LEHERT P: Effect of oral acamprosate on abstinence in patients with alcohol dependence: a randomized clinical trial. (Submitted).
   Google Scholar
• MANN K: Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs (2004) 18(8):485–504.
   PubMed Web of Science ®Google Scholar
• MANN K, LEHERT P, MORGAN MY: The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res. (2004) 28(1):51–63.
   PubMed Web of Science ®Google Scholar
• BOUZA C, MAGRO A, MUNOZ A, AMATE JM: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction (2004) 99(7):811–828.
   PubMed Web of Science ®Google Scholar
• HOPKINS JS, GARBUTT JC, POOLE CL, WEST SL, CAREY TS: Naltrexone and aamprosate: meta-analysis of two medical treatments for alcoholism (Abstr.). Alcohol Clin. Exp. Res. (2002) 26:130A.
   Google Scholar
• SCHNEIDER E, SAIKALI K, ZHANG D, GAGE A: Acamprosate promotes abstinence in alcohol-dependent patients who relapse during treatment (Abstr.). Alcohol. Clin. Exp. Res. (2005) 29:160A.
   Web of Science ®Google Scholar
• O'MALLEY SS, JAFFE AJ, CHANG G et al.: Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch. Gen. Psychiatry (1996) 53(3):217–224.
   Google Scholar
• FEENEY GF, YOUNG RM, CONNOR JP, TUCKER J, MCPHERSON A: Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust. N Z. J. Psychiatry (2002) 36(5):622–628.
   PubMed Web of Science ®Google Scholar
• HAMMARBERG A. WENNBERG P, BECK 0, FRANCK J: A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol Alcohol. (2004) 39(3):251–255.
   PubMed Web of Science ®Google Scholar
• SOYKA M, PREUSS U, SCHUETZ C: Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. Drugs R ebD (2002) 3(1):1–12.
   Google Scholar
• PELC I, ANSOMS C, LEHERT P et al.: The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol. Clin. Exp. Res. (2002) 26(10):1529–1538.
   PubMed Web of Science ®Google Scholar
• •Large multi-country study reporting the efficacy of acamprosate with a variety of psychosocial support.
   Google Scholar
• DE WILDT WA, SCHIPPERS GM, VAN DEN BRINK W, POTGIETER AS, DECKERS F, BETS D: Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol. (2002) 37(4):375–382.
   Google Scholar
• COMBINE STUDY RESEARCH GROUP: Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol. Clin. Exp. Res. (2003) 27(7):1107–1122.
   PubMed Web of Science ®Google Scholar
• •Description of the rationale and methodology in a combined pharmacotherapy study.
   Google Scholar
• LITTLETON J, ZIEGLGANSBERGER W: Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am. J. Addict. (2003) 12\(Suppl. 1):53–S11.
   Google Scholar
• •Review of the mechanisms of action of acamprosate and naltrexone.
   Google Scholar
• KIM SG, HAN BD, PARK JM, KIM MJ, STROMBERG MF: Effect of the combination of naltrexone and acamprosate on alcohol intake in mice. Psychiatry Clin. Neurosci. (2004) 58(1):30–36.
   PubMed Web of Science ®Google Scholar
• Camprale (package insert). Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, Inc., St. Louis, USA (2004).
   Google Scholar
• MASON BJ: Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur. Neuropsychopharmacol (2003) 13(6):469–475.
   PubMed Web of Science ®Google Scholar
• GRANT KA, WOOLVERTON WL: Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem. Behav. (1989) 32(3):607–611.
   PubMed Web of Science ®Google Scholar
• MASON BJ, GAGE A, CHABAC S, GOODMAN AM: Acamprosate resopnse in clincial sub-types of alcohol dependence (Abstract) Proceedings of thel5th Annual American Academy of Addiction Psychiatry Meeting, San Juan, PR (December 9–12, 2004).
   Google Scholar
• SCHADLICH PK, BRECHT JG: The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics (1998) 13(6):719–730.
   Google Scholar
• PALMER AJ, NEESER K, WEISS C, BRANDT A, COMTE S, FOX M: The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. (2000) 35(5):478–492.
   PubMed Web of Science ®Google Scholar
• ANNEMANS L, VANOVERBEKE N, TECCO J, D'HOOGHE D: Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur. Addict. Res. (2000) 6(2):71–78.
   PubMed Web of Science ®Google Scholar
• RYCHLIK R, SIEDENTOP H, PFEIL T,DANIEL D: Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Ent: Addict. Res. (2003) 9(2):59–64.
   PubMed Web of Science ®Google Scholar
• ERDER MH, WEYCKER D, OSTER G: Economic costs of acamprosate treatment among alcohol-dependent patients initiating an abstinence program (Abstr.). Alcohol. Clin. Exp. Res. (2005) 29:172A.
   Web of Science ®Google Scholar